LOG IN
SIGN UP
MARKET
ALPN
ALPN
Alpine Immune Sc
NASDAQ
6.30
-0.44
-6.53%
After Hours: 6.30 0 0.00% 16:01 12/06 EST
OPEN
6.69
PREV CLOSE
6.74
HIGH
6.82
LOW
6.14
VOLUME
69.24K
TURNOVER
0
52 WEEK HIGH
14.40
52 WEEK LOW
4.820
MARKET CAP
289.26M
P/E (TTM)
-3.5358
1D
5D
1M
3M
1Y
5Y
Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
SEATTLE, November 22, 2022--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will participate in a ...
Business Wire · 11/22 21:15
SVB Leerink Initiates Coverage On Alpine Immune Sciences with Outperform Rating, Announces Price Target of $16
Benzinga · 11/21 11:39
--SVB Securities Initiates Alpine Immune Sciences With Outperform Rating, Sets Price Target at $16
--SVB Securities Initiates Alpine Immune Sciences With Outperform Rating, Sets Price Target at $16
MT Newswires · 11/21 08:04
Alpine Immune Sciences Third Quarter 2022 Earnings: Misses Expectations
Alpine Immune Sciences ( NASDAQ:ALPN ) Third Quarter 2022 Results Key Financial Results Revenue: US$8.37m (down 1.7...
Simply Wall St. · 11/16 10:58
BRIEF-Alpine Immune Sciences Reports Third Quarter 2022 Financial Results
Reuters · 11/14 21:42
Alpine Immune Sciences GAAP EPS of -$0.42 misses by $0.32, revenue of $8.37M misses by $10.31M
Seekingalpha · 11/14 21:23
Alpine Immune Sciences Q3 EPS $(0.42) Up From $(0.55) YoY, Sales $8.37M Down From $8.52M YoY
Benzinga · 11/14 21:10
-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Reports Q3 Revenue $8.4M
-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Reports Q3 Revenue $8.4M
MT Newswires · 11/14 16:12
About ALPN
Alpine Immune Sciences, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The Company's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. Its product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
Webull offers kinds of Alpine Immune Sciences Inc stock information, including NASDAQ:ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ALPN stock methods without spending real money on the virtual paper trading platform.